Check out the cover story in the new Medical Marketing & Media, which takes a look at an issue that is very important to AstraZeneca: using data to inform how payers and providers evaluate medicines for coverage.
For instance, AstraZeneca has leveraged clinical evidence derived from administrative claims and (electronic health records) to look at the effect of formulary decisions on total cost of care for some late-stage commercial products.
“We showed that the removal of a branded medicine in our portfolio from the preferred-tier status actually resulted in higher overall costs, which were related to cost of office and [ER] visits as well as disease-state related tests,” reports Brian Sweet, AstraZeneca executive director of health alliances. Considering such study results has helped the company “solidify tier-placement decisions with respect to our medication that are more favorable than what you would expect with a generic market where we have to compete with a late-stage commercial product,” he adds.
Give the whole article a read, which looks at AstraZeneca’s real world evidence collaboration with HealthCore, the health outcomes research subsidiary of WellPoint, Inc. – as well as what is going on at other companies.
MM&M takes a look at how pharmaceutical companies and payers are using “deep data” on to benefit patients.